ReviewMedicine2025
An infant with IVIG-resistant Kawasaki disease requiring repeated glucocorticoids therapy: A case report and literature review.
Review in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleKawasaki disease (KD) is an acute systemic vasculitis predominantly affecting children, characterized by fever, chapped lips, strawberry tongue, conjunctival hyperemia, rash, and cervical lymphadenopathy. The most severe complication associated with KD is the development of coronary artery abnormalities. PATIENT CONCERNS: A 1-year and 2-month-old girl was admitted to the hospital with persistent fever, rash, and elevated inflammatory markers. DIAGNOSES: Despite 36 hours of intravenous immunoglobulin (IVIG) therapy, she remained febrile and was classified as IVIG-resistant.
interventionsMethylprednisolone was administered for 13 days; however, tapering to a single daily dose resulted in symptom recurrence. OUTCOMES: A subsequent course of intravenous methylprednisolone, administered over 42 days, resolved her symptoms, with follow-up evaluations demonstrating normal echocardiograms and electrocardiograms. The duration of methylprednisolone treatment exceeded standard guideline recommendations for KD; however, the patient achieved full recovery without adverse effects. LESSONS: This case highlights the potential efficacy of glucocorticoids as a treatment option for IVIG-resistant KD and emphasizes the necessity for further research into their role as first-line therapy, particularly in patients with IVIG intolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.